 CAMBRIDGE, Mass., June 16, 2021 PRNewswire -- Blueprint Medicines Corporation NASDAQ: BPMC today announced that the U.S. Food and Drug Administration FDA has approved AYVAKITTM avapritinib for the treatment of adult patients with advanced systemic mastocytosis Advanced SM, including aggressive SM ASM, SM with an associated hematological neoplasm SM-AHN and mast cell leukemia MCL. 